154 related articles for article (PubMed ID: 24152675)
1. Synthesis and structure-activity relationships of amino acid conjugates of cholanic acid as antagonists of the EphA2 receptor.
Russo S; Incerti M; Tognolini M; Castelli R; Pala D; Hassan-Mohamed I; Giorgio C; De Franco F; Gioiello A; Vicini P; Barocelli E; Rivara S; Mor M; Lodola A
Molecules; 2013 Oct; 18(10):13043-60. PubMed ID: 24152675
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor.
Tognolini M; Incerti M; Hassan-Mohamed I; Giorgio C; Russo S; Bruni R; Lelli B; Bracci L; Noberini R; Pasquale EB; Barocelli E; Vicini P; Mor M; Lodola A
ChemMedChem; 2012 Jun; 7(6):1071-83. PubMed ID: 22529030
[TBL] [Abstract][Full Text] [Related]
3. Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
Incerti M; Tognolini M; Russo S; Pala D; Giorgio C; Hassan-Mohamed I; Noberini R; Pasquale EB; Vicini P; Piersanti S; Rivara S; Barocelli E; Mor M; Lodola A
J Med Chem; 2013 Apr; 56(7):2936-47. PubMed ID: 23489211
[TBL] [Abstract][Full Text] [Related]
4. Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction.
Pala D; Castelli R; Incerti M; Russo S; Tognolini M; Giorgio C; Hassan-Mohamed I; Zanotti I; Vacondio F; Rivara S; Mor M; Lodola A
J Chem Inf Model; 2014 Oct; 54(10):2621-6. PubMed ID: 25289483
[TBL] [Abstract][Full Text] [Related]
5. Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis.
Giorgio C; Russo S; Incerti M; Bugatti A; Vacondio F; Barocelli E; Mor M; Pala D; Hassan-Mohamed I; Gioiello A; Rusnati M; Lodola A; Tognolini M
Biochem Pharmacol; 2016 Jan; 99():18-30. PubMed ID: 26462575
[TBL] [Abstract][Full Text] [Related]
6. Target hopping as a useful tool for the identification of novel EphA2 protein-protein antagonists.
Tognolini M; Incerti M; Pala D; Russo S; Castelli R; Hassan-Mohamed I; Giorgio C; Lodola A
ChemMedChem; 2014 Jan; 9(1):67-72. PubMed ID: 24115725
[TBL] [Abstract][Full Text] [Related]
7. UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations.
Hassan-Mohamed I; Giorgio C; Incerti M; Russo S; Pala D; Pasquale EB; Zanotti I; Vicini P; Barocelli E; Rivara S; Mor M; Lodola A; Tognolini M
Br J Pharmacol; 2014 Dec; 171(23):5195-208. PubMed ID: 24597515
[TBL] [Abstract][Full Text] [Related]
8. The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells.
Giorgio C; Mena P; Del Rio D; Brighenti F; Barocelli E; Hassan-Mohamed I; Callegari D; Lodola A; Tognolini M
Mol Nutr Food Res; 2015 Nov; 59(11):2155-67. PubMed ID: 26307544
[TBL] [Abstract][Full Text] [Related]
9. Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling.
Gomez-Soler M; Petersen Gehring M; Lechtenberg BC; Zapata-Mercado E; Hristova K; Pasquale EB
J Biol Chem; 2019 May; 294(22):8791-8805. PubMed ID: 31015204
[TBL] [Abstract][Full Text] [Related]
10. Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation.
Giorgio C; Hassan Mohamed I; Flammini L; Barocelli E; Incerti M; Lodola A; Tognolini M
PLoS One; 2011 Mar; 6(3):e18128. PubMed ID: 21479221
[TBL] [Abstract][Full Text] [Related]
11. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.
Noberini R; Koolpe M; Peddibhotla S; Dahl R; Su Y; Cosford ND; Roth GP; Pasquale EB
J Biol Chem; 2008 Oct; 283(43):29461-72. PubMed ID: 18728010
[TBL] [Abstract][Full Text] [Related]
12. Architecture of Eph receptor clusters.
Himanen JP; Yermekbayeva L; Janes PW; Walker JR; Xu K; Atapattu L; Rajashankar KR; Mensinga A; Lackmann M; Nikolov DB; Dhe-Paganon S
Proc Natl Acad Sci U S A; 2010 Jun; 107(24):10860-5. PubMed ID: 20505120
[TBL] [Abstract][Full Text] [Related]
13. Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists.
Callegari D; Pala D; Scalvini L; Tognolini M; Incerti M; Rivara S; Mor M; Lodola A
Molecules; 2015 Sep; 20(9):17132-51. PubMed ID: 26393553
[TBL] [Abstract][Full Text] [Related]
14. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase.
Ferluga S; Hantgan R; Goldgur Y; Himanen JP; Nikolov DB; Debinski W
J Biol Chem; 2013 Jun; 288(25):18448-57. PubMed ID: 23661698
[TBL] [Abstract][Full Text] [Related]
15. Effect of EphA2 knockdown on melanoma metastasis depends on intrinsic ephrinA1 level.
Mo J; Zhao X; Dong X; Liu T; Zhao N; Zhang D; Wang W; Zhang Y; Sun B
Cell Oncol (Dordr); 2020 Aug; 43(4):655-667. PubMed ID: 32291572
[TBL] [Abstract][Full Text] [Related]
16. Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor.
Lema Tomé CM; Palma E; Ferluga S; Lowther WT; Hantgan R; Wykosky J; Debinski W
J Biol Chem; 2012 Apr; 287(17):14012-22. PubMed ID: 22362770
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach.
Ferrari FR; Giorgio C; Zappia A; Ballabeni V; Bertoni S; Barocelli E; Scalvini L; Galvani F; Mor M; Lodola A; Tognolini M
Biochem Pharmacol; 2023 Mar; 209():115452. PubMed ID: 36792038
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship analysis of peptides targeting the EphA2 receptor.
Mitra S; Duggineni S; Koolpe M; Zhu X; Huang Z; Pasquale EB
Biochemistry; 2010 Aug; 49(31):6687-95. PubMed ID: 20677833
[TBL] [Abstract][Full Text] [Related]
19. An ephrin mimetic peptide that selectively targets the EphA2 receptor.
Koolpe M; Dail M; Pasquale EB
J Biol Chem; 2002 Dec; 277(49):46974-9. PubMed ID: 12351647
[TBL] [Abstract][Full Text] [Related]
20. EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model.
Tandon M; Vemula SV; Sharma A; Ahi YS; Mittal S; Bangari DS; Mittal SK
J Gene Med; 2012 Feb; 14(2):77-89. PubMed ID: 22228563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]